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Abstract: High-dose chemotherapy and autologous transplantation of hematopoietic cells is 
a crucial treatment option for hematologic malignancy patients. Current mobilization regimes 
often do not provide adequate numbers of CD34+ cells. The chemokine receptor CXCR4 and 
ligand SDF-1 are integrally involved in homing and mobilization of hematopoietic progenitor 
cells. Disruption of the CXCR4/SDF-1 axis by the CXCR4 antagonist, plerixafor, has been 
demonstrated in Phase II and Phase III trials to improve mobilization when used in conjunction 
with granulocyte colony-stimulating factor (G-CSF). This approach is safe with few adverse 
events and produces significantly greater numbers of CD34+ cells when compared to G-CSF 
alone. New plerixafor initiatives include use in volunteer donors for allogeneic hematopoietic 
cell transplant and in other disease targets.
Keywords: plerixafor, autologous hematopoietic cell transplant, CD34, lymphoma, myeloma, 
granulocyte colony-stimulating factor (G-CSF)
Core Evidence clinical impact summary for plerixafor/autologous progenitor cell   
mobilization
Outcome 
measure
Evidence Implications
Disease-oriented  
evidence
Multiple myeloma Randomized clinical trial (31) Safe and efficient HPC mobilization for  
autologous bone marrow transplant
Non-Hodgkin’s 
lymphoma
Randomized clinical  
trial (26). 
Safe and efficient HPC mobilization for  
autologous bone marrow transplant
Patient-oriented 
evidence
Clinical trials indicating safety 
and efficacy
Higher percentage of patients are mobilized  
to facilitate autologous transplants 
Safe approach 
May be beneficial in patients who are heavily  
treated and particularly those treated with  
lenalidomide
Economic evidence  More expensive than using 
G-CSF alone
Successful HPC mobilization with fewer attempts  
may account for part of the cost difference.  
Possibility of autologous transplants to save  
further therapy or prolong disease-free  
intervals may also account for part of the  
cost difference as mobilization rate is higher using 
plarixafor.  
Abbreviations: G-CSF, granulocyte colony-stimulating factor; HPC, hematopoietic progenitor cell.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Introduction
Hematopoietic stem cell (HSC) transplantation is a crucial 
treatment option for   hematological malignancies. Current 
mobilization regimes frequently result in   inadequate num-
bers of hematopoietic progenitor cell (HPC). The chemokine 
  receptor CXCR4 and ligand SDF-1 are integrally involved 
in homing and mobilization of HPCs. Disruption of the 
SDF-1/CXCR4 axis by the CXCR4 antagonist, plerixafor, 
was demonstrated in clinical trials to improve mobilization 
when it was included in the mobilization regimen. Plerixa-
for exerts its effect by reversibly blocking the ability of 
HPCs to bind to the bone marrow matrix. When used with 
granulocyte   colony-stimulating factor (G-CSF), plerixafor 
helps increase the number of these progenitor cells in the 
peripheral blood.
In this review, we analyze the literature pertinent to 
plerixafor   development, its safety, and the evidence for 
its clinical efficacy as a HPC-mobilizing agent in patients 
with non-Hodgkin lymphoma (NHL) and multiple myeloma 
(MM) requiring autologous cell transplantation.
History and drug development
Plerixafor was originally developed as a potential anti-
HIV agent because it antagonizes the chemokine receptor 
4 (CXCR4), which serves as a coreceptor for the entry of 
T-lymphotropic HIV strains into host T-lymphocyte cells. 
During pharmacokinetic studies of the drug, leukocytosis 
was observed.1,2 Hendrix et al1 reported that the plasma 
concentration of plerixafor declined gradually after a single 
intravenous dose, while the white blood cell count gradually 
increased, reaching a maximum count of ∼3 times its baseline 
at 6 h. This leukocytosis appeared to result from CD34+ cell 
mobilization.
Further work demonstrated that the administration of 
plerixafor resulted in a consistent increase in the number of 
CD34+ cells in the peripheral blood, suggesting that it could 
be used as a potential CD34+-cell-mobilizing agent in the 
setting of autologous transplantation.2–10
Mechanism of action
CXCR4 is a chemokine receptor expressed on several cell 
types including CD34+ cells. Stromal-derived factor-1α 
(SDF-1α), also known as CXCL12, is a member of the 
chemokine superfamily of chemotactic cytokines produced 
predominantly by mesenchymal stromal cells of tissues 
such as bone marrow. Chemotaxis of CXCR4 toward 
SDF-1α plays an important role in the trafficking and 
  homing of HPCs to the bone marrow compartment. CXCR4 
helps anchor cells to the marrow matrix, either directly 
via SDF-1α or through the induction of other adhesion 
  molecules. Plerixafor is a receptor antagonist that revers-
ibly blocks the binding of CXCR4 to SDF-1α. Disruption 
of the binding of CXCR4 and SDF-1α results in the rapid 
egress of CD34+ cells from the bone marrow matrix into 
the circulation.11–16
Further, plerixafor synergistically augments the mobi-
lization effect of G-CSF on CD34+cells.5 Hematopoietic 
differentiation of transplanted CD34+cells was similar after 
plerixafor or G-CSF mobilization methods.17
Cells mobilized by a combination of plerixafor and 
G-CSF are not simply a mixture of cells mobilized by each 
agent separately, but represent a unique biological profile 
as gene expression of the cells was different.18,19 Some 
of the genes were upregulated in the cells mobilized by 
the combination of plerixafor and G-CSF, whereas they 
were not upregulated in the cells mobilized by either agent 
alone.18 Studies on patients with NHL or MM indicated that 
mobilization of CD34+/CD38− cells, a more primitive subset 
of CD34+ cells, was eightfold higher with the   addition of 
plerixafor to a G-CSF regimen when compared to G-CSF 
alone.19
Pharmacokinetics
Plerixafor is not absorbed after oral administration but it 
rapidly penetrates tissues after subcutaneous injection. Its 
distribution is confined mostly to the extravascular space 
and the distribution half-life is about 0.3–0.4 h. This agent 
is bound to human plasma proteins up to about 60%.20 It is 
neither metabolized by human liver microsomes nor does it 
inhibit or induce cytochrome P450 enzymes.
The major route of elimination is through the kidney. 
Approximately 70% of the dose was excreted unchanged 
in the urine during the first 24 h after a single subcutaneous 
injection of 240 µg/kg in healthy volunteers.1,21
In NHL or MM patients, the mean t½ was 5.1 h,   similar 
to that in healthy subjects.22 A statistically significant 
  correlation was noted between renal function (as determined 
by creatinine clearance (CrCl)) and plerixafor clearance,23,24 
as reported in phase I clinical trials. The t½ was delayed and 
the AUC increased in subjects with moderate or severe renal 
impairment.
Safety and therapeutic efficacy
Phase i clinical trials
Phase I pharmacokinetic (PK) and pharmacodynamic (PD) 
studies in healthy volunteers demonstrated that plerixafor Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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administered either alone or in combination with G-CSF 
resulted in dose-dependent mobilization of CD34+ cells in 
the peripheral blood.1
PK parameters for NHL and MM patients were 
  comparable to normal volunteers. Plerixafor was   rapidly 
absorbed after subcutaneous administration with no 
  observable lag time; peak plasma concentrations occurred 
0.5 h after administration in most patients. Plerixafor was 
cleared rapidly, with a median terminal half-life of 4.6 h. 
The median maximum increase in the number of CD34 
circulating cells from baseline was 4.2 (range, 3.0–5.5), 
with the maximum increase noted approximately 10 h after 
plerixafor injection. Plerixafor was safe and   effective in 
mobilizing CD34+ cells for transplantation.21,23,24   Toxicities 
greater than NCI-CTC grade 1 were rarely observed; the 
predominantly reported adverse events were diarrhea and 
vomiting.
Phase ii trials
In a Phase II trial conducted in NHL patients, plerixafor 
subcutaneous injection after four consecutive days of G-CSF 
resulted in significant increment of the blood CD34+ cells 
followed by normalization of the cell count within 24 h after 
cessation of plerixafor.15
In another study, the combination of G-CSF with plerixafor22 
significantly increased the CD34+ cell count in patients with 
NHL and MM. The median number of CD34+ cells collected 
by five consecutive apheresis was 5.7 × 106 cells/kg in NHL 
patients and 12.0 × 106 cells/kg in MM patients.
Additionally, Stiff et al reported that in patients with NHL 
and MM, the combination of plerixafor and G-CSF was 
well tolerated and resulted in a superior yield of CD34+ cells 
mobilization.25
Phase iii trials
Two randomized, double-blind, placebo-controlled, HPC 
mobilization Phase III studies were conducted in patients 
undergoing autologous HPC transplantation for NHL 
(n = 298) and MM (n = 302).26–31 The studies were of 
identical duration (12 months), shared general design 
characteristics, and assessed the effects of the addition of 
plerixafor to G-CSF in terms of mobilization efficiency 
and graft durability in patients undergoing four or less 
apheresis procedures.
Primary and secondary end points in the NHL study 
are listed in Table 1. Patients who failed to collect either 
0.8 × 106 CD34+ cells/kg after two apheresis days or 
2 × 106 CD34+ cells/kg or more in four apheresis days 
could enter an open-label rescue procedure with plerixafor 
plus G-CSF.
The addition of plerixafor to G-CSF for HPC mobilization 
resulted in a significantly higher CD34+ cell collection in 
fewer days of apheresis and a higher proportion of patients 
(90% versus 55.4%) proceeding to transplant than with 
G-CSF alone.27–29 A statistically significant greater number 
of patients achieved the primary end point of the study 
in the plerixafor plus G-CSF arm (59.3% versus 19.6%; 
P , 0.001). This group also attained the minimum collec-
tion after 1 day (56.5 versus 20.4; P , 0.001) and by the 
end of the treatment period (86.7 versus 47.3), these patients 
also obtained a significantly higher number of CD34 cells 
(Table 1).26–28 About 7% of patients initially treated with the 
combination of plerixafor and G-CSF therapy required the 
rescue procedure compared to 52.7% in the placebo plus 
G-CSF arm. Most subjects were salvaged with the crossover 
to the plerixafor-containing arm and attained an adequate 
HPC dose for transplantation.
Considering its significant mobilization efficiency, 
similar median time to engraftment, and mortality rate 
  during 12 months of follow-up, these data demonstrated that 
plerixafor in combination with G-CSF may be recommended 
for patients who have difficulty mobilizing CD34+ cells for 
autologous transplantation.
The second Phase III mobilization trials enrolled 
MM patients in first or second complete or partial remis-
sion.29–31 Randomization was based on baseline platelet 
count (,200 × 103/µL versus $200 × 103/µL) and planned 
single versus tandem autograft. The primary and   secondary 
  endpoints were the same as in the NHL study except that the 
target for CD34 cell dose was increased to 6 × 106 CD34+ cells/
kg in two or fewer apheresis days, rather than 5 × 106 CD34+ 
cells/kg in four or fewer apheresis procedures. Additional 
Table 1 Summary of the results of the non-Hodgkin lymphoma 
phase iii clinical trial
Results Plerixafor +  
G-CSF  
N = 150
Placebo + 
G-CSF 
N = 148
Met primary end point (%) 59.3 19.6
Achieved minimum  
collection (%)
86.7 47.3
Mean no. of CD34+ 
(×106 cells/kg)
6.06 4.09
Median time to platelet  
engraftment (days)
20 20
Median time to wBCs  
engraftment (days)
10 10
Follow-up period (months) 12 12
One-year mortality (%) 12 12.8Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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provisions for the use of open-label plerixafor plus G-CSF 
included failure to collect at least 0.8 × 106 CD34+ cells/kg 
after two apheresis days or 2 × 106 CD34+ cells/kg in four 
apheresis days, or patients who were scheduled for tandem 
transplantation in whom ,4 × 106 CD34+ cells/kg were 
collected.
Results of this trial demonstrated a statistically supe-
rior outcome with the combination of plerixafor and 
G-CSF in terms of meeting the primary and secondary 
end points (Table 2). Graft durability rate in both arms 
after 100 days, mean platelet and neutrophil count, as 
well as the mean hemoglobin concentration 100 days 
after transplantation and 12 months after were the same 
in both arms.30
In this study, tandem transplantation was planned for 48% 
of patients in the plerixafor arm and for 43.5% of patients 
in the placebo arm. The actual percentage of patients who 
underwent tandem transplantation was less than planned 
(21.6% and 15.6%, respectively) due to the failure to   collect 
sufficient CD34+ cells.29–31 In a post hoc analysis of these 
two Phase III clinical studies, infused CD34+ cell dose was 
not associated with hematopoietic recovery for neutrophil, 
lymphocyte, and red blood cell in either NHL or MM 
patients.32
Dosing and administration
On the basis of the above clinical evidence, the Food and Drug 
Administation approved plerixafor as a mobilization agent at 
a dose of 240 µg/kg actual body weight of the patient. The 
prescription uses subcutaneous injection beginning on the 
fourth day of G-CSF pretreatment.20 In most published stud-
ies, plerixafor was administered 10 h prior to apheresis for 
up to a total of four consecutive days, or until the target was 
met. This approach had been logistically difficult to execute, 
as it meant the patient typically would have to come into the 
treatment center approximately at 10:00 p.m. in the evening 
before apheresis; the procedure had to begin at 8:00 a.m. 
the next morning. More recently, several abstracts at the 
American Society of Hematology Annual Meeting in 2009 
reported that there were no significant differences in apheresis 
yield between patients who received plerixafor 5–15 h prior 
to apheresis.33,34 With this updated information, many centers 
have altered their practice. At our institution, patients come to 
our treatment area at 5:00 p.m. on the appropriate day, then 
receive the plerixafor injection, and return to begin apheresis 
the following morning at 8:00 a.m. The dose should not exceed   
40 mg/day.
Adverse events
In the two Phase III clinical studies,28,31 the most com-
mon adverse reactions associated with plerixafor in 
combination with G-CSF were gastrointestinal toxicities and 
injection site erythema. Nearly, all adverse events noted were 
mild to moderate in intensity and of short duration. Up to 37% 
and 34% of patients treated with the combination of plerixa-
for and G-CSF have reported diarrhea and nausea, when 
compared with 17% and 22% in the G-CSF and placebo arm, 
respectively. Other reported GI side effects were flatulence 
and vomiting. Two patients in the plerixafor arm experienced 
serious adverse events,28 including one patient with hypoten-
sion and dizziness after plerixafor administration and one 
patient with thrombocytopenia after apheresis. Plerixafor 
was discontinued in three NHL patients due to a generalized 
seizure, systemic reactions not specified, and a central venous 
  catheter-associated infection. All patients, however, remained 
in the study. No MM patients experienced serious adverse 
events attributed to plerixafor.31 Other investigators have 
reported potentially serious adverse events with mobilization 
procedures including leukocytosis, thrombocytopenia, tumor 
cell mobilization, splenic enlargement, and very rarely, splenic   
rupture.20
In a murine leukemia model, plerixafor mobilized labeled 
APLluc cells from marrow to the spleen and the peripheral 
blood.35 These preclinical data suggest a potential risk for 
the use of plerixafor to mobilize CD34+ cells in patients 
with acute leukemia.
Special considerations
Plerixafor dose should be reduced in patients with an estimated 
creatinine clearance ,50 mL/min. The recommended daily 
dose of the drug in this patient population is 160 µg/kg36 and 
should not exceed 27 mg/day.20 The safety of administering 
plerixafor in patients undergoing hemodialysis has not been 
Table 2 Summary of the results of the multiple myeloma phase 
iii clinical trial
Results Plerixafor +  
G-CSF  
N = 148
Placebo +   
G-CSF  
N = 154
Met primary end point (%) 71.6 34.4
Achieved minimum collection (%) 95.9 92.9
Mean no. of CD34+ ((106 cells/kg) 5.84 4.41
Median no. of apheresis to collect  
the target CD34+ cell no.
1 4
Rescue procedures (%) 0 4.6
One-year mortality (%) 4.7 3.9
Follow-up period (months) 12 12Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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determined as these patients were excluded in the above-
discussed studies.
Dosing in overweight patients has to be adjusted using 
up to 175% of ideal body weight.20
Plerixafor plus G-CSF should be used with caution in 
patients with splenic enlargement,20 although splenic rupture 
has not been reported in clinical trials.37
Potential contraindications
Plerixafor should not be used in leukemia patients because 
the drug may potentially cause mobilization of leukemic cells 
and subsequent contamination of the apheresis product.20,35 
Thrombocytopenia has also been observed in patients 
receiving plerixafor, so close platelet count monitoring in 
this group is recommended.
Plerixafor has teratogenic potential and is labeled as 
pregnancy category D.20 In pregnant animals, plerixafor 
resulted in numerous embryo–fetal toxicities such as 
anophthalmia, cardiac defects, dilatation of olfactory ven-
tricles, retarded skeletal development, and fetal death. It is 
unknown whether plerixafor is excreted in human milk.
Safety and efficacy of plerixafor in pediatric patients 
have not been established in a controlled clinical study. In 
the two Phase III clinical studies, safety and effectiveness 
did not appear to differ between elderly and young subjects. 
Caution should be exercised for geriatric patients, especially 
those with renal impairment.
New initiatives
As plerixafor has been proven to be safe and effective in 
mobilizing CD34+ cells from normal donors, its utilization 
in the setting of allogeneic transplantation is a potentially 
novel and intriguing approach.1,4
Lenalidomide therapy may impair mobilization of 
CD34+ cells.38–41 Mark et al42 evaluated the efficacy of 
cyclophosphamide in overcoming the suppressive effect 
of lenalidomide on HPC collection in myeloma patients. 
  Twenty-eight patients were included in the study and had 
received induction therapy with clarithromycin, lenalidomide, 
and dexamethasone (BiRD). Following induction, patients 
underwent HPC collection either with G-CSF alone, or G-CSF 
and cyclophosphamide (Cy) for mobilization. Approximately 
33% of patients who received G-CSF alone were not able 
to collect adequate HPC; however, all of the patients who 
received Cy had successful collection (P , 0.0001). The 
authors concluded that Cy was effective in HPC mobilization 
of patients previously receiving lenalidomide.42 The use of 
Cy as a HPC-mobilizing agent, however, delays ASCT time 
to autograft and increases the risk of neutropenic fever and 
hospitalization.
Micallef et al43 reported retrospectively the use 
of plerixafor in MM patients previously treated with 
lenalidomide; 40 patients had previous mobilization attempts 
and 20 patients were undergoing initial mobilization. 
The overall median number of CD34+ cells collected was 
5.6 × 106 CD34+ cells/kg. Eighty percent of those who 
had previous mobilization attempts were able to achieve 
a minimum goal of $2 × 106 CD34+ cells/kg. In those 
patients receiving plerixafor and G-CSF as initial mobili-
zation attempt, all achieved the minimal goal of $2 × 106 
CD34+ cells/kg.43
Recently, the International Myeloma Working Group 
(IMWG) published guidelines for HPC collection following 
initial therapy with thalidomide-, lenalidomide-, or 
bortezomib-containing regimens. The IMWG recommends 
that patients undergo early mobilization of HPC (prefer-
ably within the first four cycles of initial therapy). They 
also recommended that those patients aged more than 65 
years and those who have received newer agents, including 
lenalidomide, undergo mobilization with either reduced-dose 
Cy and G-CSF, or G-CSF alone, with addition of plerixa-
for and G-CSF if the first leukapheresis attempt results in 
.2 × 106 CD34+ cells/kg collected. They could not recom-
mend up front use of plerixafor in this setting until further 
clinical trials were completed.44
Plerixafor also may have a role in leukemia chemosensi-
tization via its possible mobilization of leukemia cells.35 This 
strategy of rendering the acute myeloid leukemia cells more 
amenable to be targeted by chemotherapy is being tested in 
clinical trials.45
Finally, in other preclinical studies, plerixafor may 
exert beneficial effects in the treatment of inflammatory 
diseases such as rheumatoid arthritis and asthma. 
  Ostensibly, the salutary effects may result from inhibition 
of the reaction between CXCR4 and SDF-1α involved 
in the pathogenesis of inflammation.13,46,47 The value of 
this therapeutic strategy has not yet been tested in the 
clinical arena.
Summary
Plerixafor is approved for use in combination with G-CSF 
for CD34+ cells mobilization for subsequent autologous 
transplantation in NHL or MM patients. The combination 
of plerixafor and G-CSF is superior to G-CSF alone in the 
number of CD34+ cells collected and the number of required 
apheresis procedures.Core Evidence 2011:6 submit your manuscript | www.dovepress.com
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Other potential beneficial therapeutic uses of plerixafor 
remain to be investigated. These include its use in 
mobilization failures in more heavily treated patients or in 
patients given agents known to impair mobilization such as 
lenalidomide. Other potential uses are the mobilization of 
leukemic blasts in order to render them more susceptible to 
chemotherapy effect, use in mobilization of volunteer donors 
in the allograft setting, and possibly its use in chronic inflam-
matory disorders.
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